Admission HbA1C in Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Target Follow-Up Duration:||6 Months|
|Official Title:||Observational Study on the Prognostic Relevance of Admission Glycated Hemoglobin (HbA1C) in Patients With Aneurysmal Subarachnoid Hemorrhage|
- modified Rankin score [ Time Frame: 6 month after discharge ]
- Incidence of DCI related new infarction on discharge ct scan [ Time Frame: at discharge, approx. 14-21days after admission ]Incidence of new infarction on discharge ct scan not attributable to causes other then DCI.
|Study Start Date:||July 2012|
|Study Completion Date:||December 2014|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
aneurysmal subarachnoid hemorrhage
observational, no intervention
In patients suffering from aneurysmal subarachnoid hemorrhage (aSAH), hyperglycemia is considered an adverse prognostic factor. Glycated hemoglobin (or HbA1c) can be measured to estimate the average plasma glucose concentration over prolonged periods of time, thus determination of glycated hemoglobin at admission after aSAH serves as an approximation of blood glucose levels in the weeks preceding aneurysm rupture.
In this patient registry admission HbA1c within 72 hours after confirmed aneurysmal subarachnoid hemorrhage in patients aged over 18 years is determined and correlated with clinical course and neurological outcome after 6 month as determined by modified Rankin score. Additionally, patients are monitored for incidence of delayed cerebral ischemia (DCI) and the incidence of new infarction on the discharge ct scan attributable to DCI. General treatment of cerebral aneurysm and subarachnoid hemorrhage in all patients follows international guidelines.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02081820
|Department of Neurosurgery, Heinrich-Heine-University Düsseldorf|
|Düsseldorf, NRW, Germany, 40225|
|Principal Investigator:||Kerim Beseoglu, M.D.||Department of Neurosurgery, Heinrich-Heine-University, Düsseldorf|